MuscleOnGLPHome/Research/October 13-19, 2026
Weekly research roundup
GLP-1 and muscle research: October 13-19, 2026
This week's papers span body composition on GLP-1 medications, physical function during semaglutide treatment, and the muscle-sarcopenia risk landscape in diabetes. A recurring theme is the importance of structured exercise alongside pharmacotherapy — and the need for better functional monitoring beyond the scale.
How to read this
- This roundup is compiled automatically from the abstracts of newly published research and is a neutral summary, not medical advice, not peer review, and not an endorsement. Studies vary in quality and preprints are not yet peer-reviewed. Read the linked source and talk to your clinician before changing anything.
Glucose-Lowering Therapies in Type 2 Diabetes-Associated Sarcopenia: Mechanisms, Clinical Evidence and a Muscle-Centred Framework.
This narrative review examines the bidirectional relationship between type 2 diabetes and sarcopenia, and appraises major glucose-lowering drug classes — including GLP-1 receptor agonists and SGLT2 inhibitors — on muscle-relevant outcomes such as body composition, strength, and physical performance. The authors caution that lean-mass reductions seen on DXA or BIA during GLP-1 RA use should be interpreted carefully, as they occur in the context of overall weight loss and may reflect changes in body water rather than true contractile muscle loss. They argue that lean-mass estimates alone are insufficient to infer clinically meaningful muscle loss without concurrent assessment of muscle strength or physical performance, and propose a framework emphasizing functional monitoring, resistance exercise, nutritional optimization, and individualized targets in older or frail adults.
Why it matters: This review directly addresses the muscle and sarcopenia risk of GLP-1 RA therapy in a diabetes population, critically evaluates the measurement tools used to detect lean-mass changes, and argues for functional assessment alongside body composition metrics.
What this means for you: This adds to the case for tracking not just weight or lean-mass estimates but also strength and physical performance measures when using GLP-1 medications — worth discussing with a clinician how to incorporate functional monitoring into ongoing care.
Changes in Gait Speed During a 12-Month Multidisciplinary Obesity Management Program Including Semaglutide: A Real-World Observational Study in Japanese Adults With Musculoskeletal Disorders.
This small retrospective observational study (n=22) followed Japanese adults with obesity and musculoskeletal disorders through a 12-month multidisciplinary program combining semaglutide, nutritional counseling, and physical therapist-guided exercise. Body weight decreased significantly, and usual gait speed improved significantly. Notably, improvements in gait speed were not associated with the degree of weight loss or pain reduction; instead, participants with poorer baseline mobility showed the greatest gains. The authors suggest that obesity treatment outcomes should be evaluated by recovery of mobility, not only by weight loss.
Why it matters: This real-world study demonstrates that physical function (gait speed) can improve meaningfully during semaglutide-based treatment when structured exercise is included, and that functional gains appear independent of weight loss magnitude — highlighting the value of exercise as a co-intervention.
What this means for you: This is one more reason to prioritize clinician- or therapist-guided exercise as part of any GLP-1 medication program, particularly for those with baseline mobility limitations.
Body composition changes in patients on GLP-1 receptor agonists undergoing an intensive cardiac rehabilitation program.
This retrospective cohort study of 468 cardiac rehabilitation patients compared skeletal muscle mass (SMM) and fat mass changes between GLP-1 RA users (n=67) and non-users during an intensive, structured exercise program. After adjusting for age, sex, BMI, diabetes status, and baseline fitness, GLP-1 RA use was not associated with significantly different percent change in SMM compared to non-use. Both groups improved in cardiorespiratory fitness. The authors conclude that GLP-1 RA-based pharmacotherapy can be integrated with structured exercise programs without evidence of greater muscle loss.
Why it matters: This study directly addresses the concern that GLP-1 medications cause disproportionate skeletal muscle loss, finding no significant difference in SMM change when patients participate in a structured exercise program.
What this means for you: This adds to the case for pairing GLP-1 medication use with a structured exercise program as a strategy to support skeletal muscle mass during weight loss.
Advances in disease management and treatment outcomes for obesity and knee osteoarthritis in primary care practice.
This targeted literature review examines weight loss interventions — including lifestyle changes and GLP-1 receptor agonists such as semaglutide — in adults with obesity and knee osteoarthritis (KOA). It notes that a phase 3 clinical study demonstrated benefits of semaglutide for weight loss in adults with KOA and high BMI, with associated improvements in pain, physical function, and quality of life. The authors explicitly identify preservation of functional muscle mass and mitigation of weight regain after medication withdrawal as areas requiring further research before obesity medications can be widely adopted in KOA management.
Why it matters: The review flags preservation of functional muscle mass as an unresolved and important concern when using GLP-1 medications for obesity-related joint disease, a population where physical function is already compromised.
What this means for you: This is one more reason to discuss with a clinician how to protect muscle function — through exercise and adequate protein — when using GLP-1 medications for obesity alongside musculoskeletal conditions.
Turn the evidence into a plan
The MuscleOnGLP handbook
These studies point the same direction our guides already put into practice: resistance training and enough protein preserve muscle while you lose weight. The 30-page handbook is the full, cited protocol.
See the handbook — $5 →